BriaCell Therapeutics Corp. Announces Completion of Shares for Debt Issuance

NEXT STORY
Tiziana Granted a Patent on Methods and Use of Anti-CD3 Monoclonal Antibodies for Treatment of Crohn’s Disease
PREV STORY
First Patient Dosed in Phase I/II Trial of Renal Cancer Imaging Product in Japan
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Rexahn Phase 2a Combination Study of RX-3117 and Abraxane® in First-line Metastatic Pancreatic Cancer Patients Advances to Second Stage

Routine Safety Monitoring Committee Review Confirmed No Dose Reductions NecessaryROCKVILLE, Md., May 15, 2018 ...

author_avatar
NASDAQ Market News

argenx announces pipeline expansion and “argenx 2021” vision to build integrated immunology company at 2019 R&D Day

author_avatar
NASDAQ Market News

Eight Data Presentations at ECCMID Showcase the Broad Applicability of SCYNEXIS’ Lead Anti-infective Candidate SCY-078

Presentations support SCY-078's potential as a novel treatment for Candida infections including multidrug-resistant strains Favorable ...

author_avatar
NASDAQ Market News